IMAB362   

GtoPdb Ligand ID: 9209

Compound class: Antibody
Comment: IMAB362 is an investigational, first-in-class monoclonal antibody targeting the cell surface molecule claudin18.2 (CLDN18.2), a pan-cancer drug target [1]. Claudin-18 is a tight-junction protein. Splice variant 2 is reported to be a highly selective cell lineage marker of gastric mucosal cells. CLDN18.2 is retained on malignant transformation and is expressed in a significant proportion of primary gastric cancers and their metastases, and ectopic expression of CLDN18.2 is identified in distinct histologic subtypes of pancreatic (primary tumour and metastases) [2], esophageal, ovarian, and lung tumours [1]. The antibody binds to the first extracellular N-terminal domain which is unique to the CLDN18.2 splice variant [1-2].
No information available.
Summary of Clinical Use
IMAB362 is being evaluated in Phase 2 clinical trials for advanced gastroesophageal cancer (as monotherapy in NCT01197885) and in combination with the EOX regimen (epirubicin, oxaliplatin and capecitabine) in claudin18.2-positive gastric cancers (NCT01630083).
Mechanism Of Action and Pharmacodynamic Effects
IMAB362 inhibits tumour growth and kills cancer cells by indirect (complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity) and direct (antiproliferative and proapoptotic) mechanisms.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT01197885 Efficacy and Safety Study of Multiple Doses of IMAB362 in Patients With Advanced Gastroesophageal Cancer Phase 2 Interventional Astellas Pharma Inc
NCT01630083 Efficacy and Safety of IMAB362 in Combination With the EOX Regimen for CLDN18.2-positive Gastric Cancer Phase 2 Interventional Astellas Pharma Inc